EBOS shares gain amid executive reshuffle
Make us a preferred source
Make us a preferred source on Google
More news: EBOS shares lifted at the start of trading on the ASX after the medical product wholesaler and distributor announced Andrew McClean as the new CEO of its medical technology division.
Shares were up 2% to $31.25 by 10:55am AEST.
EBOS appoints new medical technology CEO
The news: Christchurch-headquartered medical product wholesaler and distributor EBOS Group has appointed Andrew McClean as the new CEO of its medical technology division, replacing Matt Muscio who will transition to a non-executive director role.
The context: McClean most recently served as president and CEO of SteriPack in the US between 2021 and 2023, after serving as CEO of then ASX-listed Sirtex Medical, following senior executive roles with Series Corporation, Synergy Health, Pfizer and Becton Dickinson.
He will replace Muscio, who has held the position since 2022, and will seek election as a non-executive director at this year's annual general meeting (AGM).
Meanwhile, independent director Peter Williams, who has been a director since 2013, will retire after the AGM. EBOS said his retirement is part of a "carefully considered" succession process that has included the appointments of Mark Bloom and Julie Tay as independent directors during the last two years, as well as the proposed appointment of Muscio.
What they said: EBOS chief executive John Cullity said: "Andrew is a highly entrepreneurial, results-driven executive with a wide range of experience in the medical technology sector".
"His multi-market experience, particularly across the Asia Pacific region and the US, aligns well with EBOS' diverse medical technology business and our strategy," he said.
The source: ASX announcement
